Botanix Pharmaceuticals Limited

BOT

AU000000BOT2

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:40:53 31/05/2024 am IST			5-day change	1st Jan Change
0.29 ^AUD	+3.57%		-.--%	+52.63%

21/05	Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	MT
13/05	Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	MT

Botanix Pharmaceuticals : ShareCafe ‘Hidden Gems’ Webinar

February 28, 2022 at 09:32 am IST

Botanix's Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap 'Hidden Gems' Webinar.

His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Botanix Pharmaceuticals Ltd. published this content on 28 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 February 2022 04:01:05 UTC.

Latest news about Botanix Pharmaceuticals Limited

Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	21/05	MT
Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	13/05	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index	18/03	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication	22/01	MT
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%	21/12	MT
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%	14/12	MT
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication	04/12	MT
Botanix Pharmaceuticals Limited Receives Feedback from FDA	04/12	CI
Botanix Pharmaceuticals Completes Nearly AU$14 Million Institutional Placement	01/12	MT
Botanix Pharmaceuticals to Raise AU$13.5 Million in Placement; Shares Fall 3%	27/11	MT
Botanix Pharmaceuticals Signs Telehealth Deal for Dermatological Product	24/23/24	MT
Botanix Pharmaceuticals Secures Conditional US FDA Clearance for Use of 'Sofra' Trade Name	17/23/17	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX Emerging Companies Index	18/23/18	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Botanix Pharmaceuticals Promotes COO to CEO	25/23/25	MT
Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer	25/23/25	CI
Botanix Pharmaceuticals Raises Nearly AU$13 Million Via Institutional Placement	21/23/21	MT
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea	05/23/05	MT
Botanix Pharmaceuticals Limited Announces Company Secretary Changes	17/23/17	CI
Botanix Pharmaceuticals Completes AU$10 Million Placement	13/23/13	MT
Botanix Pharmaceuticals to Raise AU$10 Million in Placement	05/23/05	MT
US FDA Completes Mid-Cycle Review of Botanix Pharmaceuticals’ Dermatological Drug	03/23/03	MT
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Botanix Pharmaceuticals' Dermatological Drug Enters US FDA Review	08/22/08	MT

Chart Botanix Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.29 AUD

Average target price

0.55 AUD

Spread / Average Target

+89.66%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
BOTANIX PHARMACEUTICALS LIMITED	+52.63%	293M
MERCK KGAA	+15.54%	77.63B
KYOWA KIRIN CO. LTD.	+12.05%	8.78B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.17%	4.93B
SK BIOPHARMACEUTICALS CO., LTD.	-14.94%	4.79B
YUHAN CORPORATION	-.--%	3.8B
INDIVIOR PLC	+21.94%	2.46B
BETTA PHARMACEUTICALS CO., LTD.	-26.63%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.75%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-37.97%	1.96B

Specialty & Advanced Pharmaceuticals

Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Pharmaceuticals

Botanix Pharmaceuticals : ShareCafe ‘Hidden Gems’ Webinar

Latest news about Botanix Pharmaceuticals Limited

Chart Botanix Pharmaceuticals Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals